AstraZeneca PLC Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2

Published: Dec 05, 2012

WILMINGTON, Del.--(BUSINESS WIRE)--Today, updated overall survival (OS) data for FASLODEX® (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed or recurred following prior endocrine therapy was presented at the 35th CTRC-AACR San Antonio Breast Cancer Symposium by the principal investigator, Angelo Di Leo, MD, Head of the Sandro Pitigliani Medical Oncology Unit.1,2,3. The final updated CONFIRM OS, performed at 75% maturity (after a minimum follow up duration of 50 months), showed a 19% relative reduction in the risk of death (hazard ratio (HR) 0.81; 95% confidence interval [CI] 0.69-0.96). No adjustments were made for multiplicity, therefore these data cannot be considered statistically significant. The median OS for FASLODEX 500 mg and 250 mg was 26.4 months and 22.3 months, respectively.2

Back to news